Anatara Lifesciences Ltd (ANR) AI Stock Analysis

• Market Cap: AU$2.84M
• Dividend Yield: N/A
• Average Volume (3M): 759.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: 1.03%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 315,950,780
• 10 Day Avg. Volume: 1,527,300
• 30 Day Avg. Volume: 759,886
• PEG Ratio: 0.25
• Price to Book (P/B): 1.91
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: AU$0.01 ▲(0.00% Upside)
• Action: Downgraded Date: 02/28/26
• Date: Action: Downgraded 02/28/26

The score is primarily held down by weak financial performance (persistent losses, negative margins, worsening cash burn, and shrinking equity). Technical indicators also reflect strong downside pressure, while valuation inputs are limited by negative earnings and no stated dividend yield.

Positive Factors

Focused pipeline (GaRP)

A focused lead program (GaRP) targeting gastrointestinal health gives the company a clear development path. Ongoing clinical/validation and regulatory work indicate methodical progression toward market entry, which supports durable value creation if trials and approvals advance.

Revenue rebound

A strong year-over-year revenue rebound signals early commercial traction or milestone income, demonstrating the business can generate top-line growth. If maintained and scaled, this underpins longer-term ability to improve margins and reduce dependency on external funding.

Partnering/commercialisation planning

Active partnering and commercialization planning is a durable strategic lever: it can accelerate market access, leverage partner distribution and reduce the firm's capital burden. Successful partnerships can materially de-risk late-stage commercialization and scale-up.

Negative Factors

Negative gross profit and margins

Persistently negative gross profit and deeply negative net margins show core costs exceed revenue, indicating the current business model is not yet economically sustainable. Without structural margin improvement, losses will continue to erode equity and limit strategic options.

High cash burn and weak cash generation

Consistent negative operating and free cash flow, with increasing burn, creates an enduring reliance on external capital. That pressures management to raise funds (dilution risk), constrains trial spending or commercialization timing, and limits runway for executing strategy.

Deteriorating balance sheet / declining equity

Sharply reduced equity and rising leverage materially weaken financial flexibility. A thin capital base limits the company's ability to fund clinical programs, negotiate favorable partner terms, or withstand setbacks, increasing long-term execution and solvency risk.

Anatara Lifesciences Ltd Business Overview & Revenue Model

Company Description

Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.

How the Company Makes Money

Anatara Lifesciences Ltd generates revenue through the development and commercialization of its proprietary health solutions. The company earns money by licensing its technologies and products to pharmaceutical and biotech companies, which in turn manufacture and distribute these solutions to the market. Anatara may also engage in strategic partnerships and collaborations to enhance its product development and market reach. Additionally, the company could receive milestone and royalty payments based on the success and sales of its licensed products.

Anatara Lifesciences Ltd Financial Statement Overview

Summary

Financial profile remains very weak: negative gross profit and deeply negative margins, ongoing net losses, worsening operating/free cash flow burn, and sharply declining equity. Revenue rebounded in FY2025, but profitability and self-funding capacity are not established.

Income Statement

Revenue rebounded in FY2025 (up ~287% YoY to ~0.97M), but the core earnings profile remains weak. Gross profit is negative in FY2024–FY2025 (negative gross margin), indicating costs exceed revenue, and losses remain substantial (FY2025 net loss ~1.95M; net margin about -202%). While the net loss is smaller than several prior years, profitability has not stabilized and margins remain deeply negative.

Balance Sheet

Leverage is still moderate with debt at ~0.41M and debt-to-equity at ~0.76 in FY2025, but this is a notable increase from recent years with minimal debt. Equity has also declined sharply (to ~0.54M in FY2025 from ~1.36M in FY2024), reflecting ongoing losses and reducing balance-sheet flexibility. Returns on equity are deeply negative, signaling continued value dilution for shareholders.

Cash Flow

Cash generation is a key pressure point: operating cash flow and free cash flow are consistently negative across all periods, and FY2025 burn worsened to about -2.27M versus ~-1.25M in FY2024. Cash outflows are running larger than reported losses (operating cash flow to net income is negative), highlighting limited self-funding capacity and ongoing reliance on external capital to sustain operations.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	223.10K	969.46K	644.03K	0.00	0.00	0.00
Gross Profit	-122.25K	-633.97K	-748.91K	-24.76K	-24.68K	-6.26K
EBITDA	-1.09M	-1.96M	-1.46M	-3.21M	-2.97M	-3.01M
Net Income	-911.79K	-1.95M	-1.45M	-2.02M	-2.53M	-2.00M
Balance Sheet
Total Assets	1.33M	1.15M	1.67M	1.42M	1.77M	4.33M
Cash, Cash Equivalents and Short-Term Investments	1.09M	101.36K	982.11K	401.18K	1.17M	3.43M
Total Debt	0.00	407.42K	0.00	0.00	65.80K	79.92K
Total Liabilities	195.91K	612.42K	306.85K	494.83K	403.35K	496.67K
Stockholders Equity	1.13M	535.97K	1.36M	924.54K	1.36M	3.83M
Cash Flow
Free Cash Flow	-404.20K	-2.27M	-1.25M	-2.26M	-2.24M	-2.10M
Operating Cash Flow	-404.19K	-2.27M	-1.25M	-2.26M	-2.23M	-2.10M
Investing Cash Flow	50.00K	0.00	50.00K	-1.73K	-56.56K	-3.98K
Financing Cash Flow	1.07M	1.39M	1.83M	1.49M	-22.44K	2.85M

Anatara Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVE	53 Neutral	AU$36.73M	-6.66	-258.19%	―	306.88%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMB	48 Neutral	AU$11.02M	-1.00	-218.76%	―	―	―
ANR	40 Underperform	AU$2.84M	-1.64	-109.45%	―	―	1.03%
ADO	40 Underperform	AU$35.68M	-10.60	-142.30%	―	110.44%	35.90%
HXL	40 Underperform	AU$2.17M	-4.31	-32.19%	―	―	46.43%
1AD	37 Underperform	AU$10.20M	-0.48	1068.18%	―	―	31.87%

Anatara Lifesciences Ltd Corporate Events

Anatara Lifesciences Seeks ASX Quotation for 2.36m New Shares

Anatara Lifesciences has applied for quotation on the ASX of 2,360,426 new ordinary fully paid shares. The securities, issued on February 25, 2026 following the exercise or conversion of existing options or other convertible instruments, will increase the company’s quoted capital base and potentially enhance liquidity for shareholders.

The application formalises the admission of these additional shares to trading under the ANR code. This incremental expansion of the register may modestly broaden market participation in the stock and reflects the take-up of previously granted equity-linked securities by holders.

The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.

Anatara Lifesciences Converts 2.36 Million Performance Rights Into Ordinary Shares

Anatara Lifesciences has converted 2,360,426 ANRAR performance rights into an equivalent number of ordinary shares for an employee, following the satisfaction of vesting conditions and the employee’s election to receive the shares. The company issued a cleansing notice confirming the shares were issued without a prospectus, that it remains compliant with relevant Corporations Act reporting and disclosure obligations, and that there is no undisclosed price-sensitive information, signalling routine capital management with no hidden regulatory or informational risks for investors.

The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.

Anatara Lifesciences Narrows Half-Year Loss as Revenue Slides

Anatara Lifesciences reported a sharp 66% fall in revenue from ordinary activities to $177,564 for the half-year ended 31 December 2025. The company’s net loss after tax attributable to members narrowed by 56% to $514,975, underscoring ongoing efforts to reduce losses despite weaker top-line performance.

Net tangible asset backing per share halved to $0.004 from $0.008 a year earlier, reflecting balance sheet pressure as the company continues to fund its operations. Directors confirmed that no dividend was paid for the half-year and do not recommend a payout, indicating a continued focus on capital preservation and reinvestment over shareholder distributions.

The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.

Anatara Flags Promising Anti-Obesity Data as Capital Raise Bolsters Pipeline Plans

Anatara Lifesciences reported that interim pre-clinical data from its Anti-Obesity Project at the University of Newcastle identified a lead candidate compound, AOC, which showed statistically significant effects in attenuating post-semaglutide weight regain and reducing visceral (perigonadal) fat in a mouse model of diet-induced obesity, supporting its potential as an oral complementary therapy to help maintain weight loss after GLP-1 treatments. Completion of detailed mechanism-of-action studies has been delayed by international supply issues with a key testing kit, with results now expected in February 2026, after which Anatara will decide on further development and commercialisation steps; during the quarter the company also completed a $1.2 million capital raise, ended with $1.035 million in cash, advanced publication-ready analysis of its GaRP gastrointestinal health program, and signalled its intention to continue evaluating strategic opportunities across the junior healthcare sector while maintaining tight financial control.

The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.

Anatara Lifesciences Reports Promising Results in Anti-Obesity Project

Anatara Lifesciences Ltd has reported promising pre-clinical results for its Anti-Obesity Project, with the candidate compound AOC showing significant potential in managing weight reduction and controlling weight gain after cessation of weight loss treatments. Although the Mechanism of Action studies have faced delays due to international supply issues, the company remains committed to advancing its research and exploring further commercial opportunities. The project aims to develop an oral complementary medication to assist in weight management, and Anatara is actively pursuing business development discussions to capitalize on these findings.

Anatara Lifesciences Announces Director’s Interest Change

Anatara Lifesciences Limited has announced a change in the director’s interest notice concerning Dr. David Brookes. The company disclosed that Dr. Brookes has disposed of 932,143 unlisted options, with no new securities acquired. This change reflects adjustments in Dr. Brookes’ holdings, which include both direct and indirect interests through various trusts and superfunds. The announcement is part of the company’s compliance with ASX listing rules, ensuring transparency in the director’s financial interests.

Anatara Lifesciences Announces Cessation of Securities

Anatara Lifesciences Ltd announced the cessation of 27,749,784 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perception regarding the company’s financial strategies.